

ADVANCES IN ANIMAL CELL  
BIOLOGY AND TECHNOLOGY  
FOR BIOPROCESSES

# ADVANCES IN ANIMAL CELL BIOLOGY AND TECHNOLOGY FOR BIOPROCESSES

Editors

**R. E. Spier**

Department of Microbiology, University of Surrey,  
Guildford, Surrey, UK

**J. B. Griffiths**

Porton, Salisbury, Wilts, UK

**J. Stephenne**

Smith Kline-Rit, Rixensart, Belgium

**P. J. Crooy**

Smith Kline-Rit, Rixensart, Belgium



EUROPEAN SOCIETY  
FOR ANIMAL CELL TECHNOLOGY  
**THE 9th MEETING**



PART OF REED INTERNATIONAL P.L.C.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means (including photocopying and recording) without the written permission of the copyright holder except in accordance with the provisions of the Copyright Act 1956 (as amended) or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 33-34 Alfred Place, London, England WC1E 7DP. The written permission of the copyright holder must also be obtained before any part of this publication is stored in a retrieval system of any nature. Applications for the copyright holder's written permission to reproduce, transmit or store in a retrieval system any part of this publication should be addressed to the Publishers.

Warning: The doing of an unauthorised act in relation to a copyright work may result in both a civil claim for damages and criminal prosecution.

This book is sold subject to the Standard Conditions of Sale of Net Books and may not be re-sold in the UK below the net price given by the Publishers in their current price list.

First published 1989

© Butterworth & Co. (Publishers) Ltd, 1989

**British Library Cataloguing in Publication Data**

European Society for Animal Cell Technology,  
(Meeting: 9th: 1988: Knokke, Belgium)  
Advances in animal cell biology for bioprocesses  
1. Animals. Cells. Culture. Techniques  
I. Title II. Spier, R. E. (Raymond E.)  
591'.0724

ISBN 0-407-01499-3

**Library of Congress Cataloging-in-Publication Data**

European Society of Animal Cell Technology.  
General Meeting (9th: 1988: Knokke-Heist, Belgium)  
Advances in animal cell biology and technology for  
bioprocesses: editors, R. E. Spier . . . [et al.],  
p. cm.  
"ESACT. European Society for Animal Cell Technology,  
the 9th Meeting."  
Bibliography: p.  
ISBN 0-407-01499-3:  
1. Animal cell biotechnology-Congresses. 2. Cytology-  
Congresses. I. Spier, R. (Raymond) II. Title.  
TP248.27.A53E93 1988  
660'.6-dc19

Printed and bound in Great Britain by  
Courier International Ltd., Tiptree, Essex

# Organizing Committee

J. Stephenne, *Meeting Secretary*

G. Charlier

P. Crooy

E. D'Hondt

P. d'Oultremont

L. Fabry

A. Miller

J. Werenne

# Sponsors

The Organizing Committee acknowledges the financial support of:

Alfa-Laval SA/NV  
Analis SA  
B. Braun Belgique SA  
Behring  
Bocknek Ltd  
CEC / DG XII  
Cellon Sarl  
Celltech Ltd  
Dalton BV  
Eli Lilly SA  
Euroclone BV  
Flow Laboratories NV  
Gibco Europe SA/NV  
Imperial Laboratories Ltd  
International Congress Consultants  
Invitron Corporation  
I.R.E.  
J.R. Scientific  
Janssen Biochimica

Jibe SPRL  
Lohmann Tierzucht GMBH  
MBR Bioreactor AG  
Medical and Veterinary Supplies Ltd  
Merck-Belgolabo NV/SA  
Millipore SA  
New Brunswick Scientific Benelux  
Pasture & Cie SPRL  
Percell Biolytica  
Pfeifer & Langen  
Pharmacia NV/SA  
Setric Genie Industriel  
Smith Kline Beckman  
Smith Kline-Rit  
Socomer SA/NV  
Solvay & Cie  
Sopar Biochem  
Van Der Heyden  
Verax Corporation

# ESACT Executive Committee, 1987–88

B. Griffiths	<i>Chairman</i>	PHLS CAMR, Porton, UK
B. Meignier	<i>Secretary/Treasurer</i>	Institut Merieux, Charbonnieres, France
J. Stephenne	<i>Meeting Secretary</i>	Smith Kline-Rit, Rixensart, Belgium
H. Katinger		University of Agriculture, Vienna, Austria
R. Mauler		Behringwerke AG, Marberg, FRG
A. Mizrahi		Israel Institute Ness-Ziona, Israel
G. F. Panina		Institut Zooprofilattico, Brescia, Italy
R. E. Spier		University of Surrey, Guildford, UK

# 9th ESACT Meeting, Knokke, Belgium

## *Session Officials*

### *Chairmen*

J. Stephenne  
B. Griffiths  
R. E. Spier  
E. T. Papoutsakis  
E. C. Beuvery  
B. Meignier  
H. Bazin  
J. P. Lecocq  
F. Horaud

### *Co-Chairmen*

G. Charlier  
J. Litwin  
H. Katinger  
E. D'Hondt  
B. Montagnon  
J. Obijeski  
A. S. Lubiniecki

# Preface

With the three recently licensed animal cell products (alpha lymphoblastoid interferons, OKT3 monoclonal antibody and tissue plasminogen activator) accounting for over half of the revenues attributable to the new biotechnologies, animal cell culture has emerged from the relative obscurity of the virus vaccine production systems to a prominence which holds both threats and opportunities. The proceedings of the ESACT meeting which are contained within this volume faithfully reflect this situation and can provide workers in this field with insights and inspirations which will help to maintain and catalyse progress in this area.

The upsurge of new knowledge and capabilities in the 'bio-area' which has characterized the last 15 years has presented a welter of opportunities for novel molecules to be used as prophylactics, therapeutics or diagnostics. The production systems which can be adapted to deliver these molecules can be listed as those which are based on chemical synthesis, animal cells in culture, other microbes and, most recently, transgenic animals. In brief, the chemical synthesis of polypeptides for use as 'chemically defined' vaccines has not yet achieved any notable success. Either the molecules are insufficiently immunogenic or they have to be constructed with both B-cell and T-cell stimulating epitopes so that their size could render their synthesis uneconomic. Other microbes have, however, had some success in generating acceptable and effective vaccinal materials such as the Hepatitis B surface antigen made from genetically engineered yeast cells and the *E. Coli*-derived Interleukin-2. Yet many recognize that for the more complex enzymes and antibodies animal cell systems remain the preferred substrate. Antigen combining materials made in non-animal cell microorganisms and consisting of little more than the antigen binding site may achieve a degree of eminence, although this area is one which has yet to emerge with a realised commercial potential. Again, transgenic animals offer exciting prospects of limitless production based on sunlight, grass and offal as the primary feed materials. Nevertheless, many problems remain with the use of whole animals for the production of biologicals – not the least of which are the requirements that the production systems should be safe, efficacious and consistent. The need to closely define, monitor and control all aspects of the production system, coupled with the known hazards of the use of whole animal based biological materials (over half of the haemophiliacs in the UK have been infected with HIV as a result of the injection of whole human blood-derived factor VIII) renders this method of production problematic. There was an interesting twist to the transgenic animal story in that one speaker (Lecocq) described the use of such transgenic animals in making the cell lines which could be used in bioreactor based cultivation systems.

The 280 delegates attending the meeting were less concerned with these issues than those which would enable them to proceed to more effective production



systems based on animal cells in culture. Thus there was much interest in, and indeed some pressure for, the delineation of a number of aliquoted cell preparations to be held by one or more of the cell depositories. These could be used with a particular medium as a consistent control system with which relative bioreactor performance could be more realistically evaluated. To some extent this thinking is a corollary to the thrust of the regulatory agency approach to using defined continuous cell line substrates for the production of biologicals.

It is possible to pick out one or two of the themes which permeated the more than 60 presentations and a similar number of posters. New techniques which were described included the use of Fluorescent Activated Cell Sorters, which seemed to be more for the characterization of the state of a culture than the isolation from a culture of those cells whose properties could be forecasted from the signals they engendered. Other techniques were presented based on acoustic densitometry and spectrophotometry. A similar range of new ideas came out of the descriptions of bioreactors where new three-dimensional microcarriers were much in evidence, as well as further developments of the materials which can be used as packing materials for static bed bioreactors. Other systems which involved the use of membranes or hollow fibres to segregate different sections of the bioreactor were also presented, and the point was well made that the volume of the bioreactor did not define the scale or scope of the system – rather the number of cells contained within the system could be a more appropriate way of indicating the system's potential productive performance. For the high cell density bioreactors some  $10^{12}$  cells may be contained in a 10–100 litre volume, equivalent to a 1000 litre reactor operating with  $10^6$  cells/ml. It is curious to note that the human body may be considered to possess about  $10^{13}$ – $10^{14}$  cells in total! The further development of this apparatus, by the use of a number of separate concentrates of medium components which are diluted to the use level as they are pumped into the bioreactor, was reported.

Media specifically designed for the serum-free growth of hybridoma cells and genetically engineered cells continue to command attention. Many papers dealt with the magic ingredient(s) which turned dross into nectar for the cells, although for the present some such papers only referred in general terms to the way in which the 'factor' was made rather than the precise recipe for its production. It could be that general medium formulations coupled with improved cell handling and weaning techniques could render such proprietary properties superfluous. Indeed, some basic research into the nature of the weaning process and the study of the basic metabolism of the way in which the cell uses the medium components would achieve marked progress in this area.

On the product side many advances seem to have been made in the area of virus vaccines, and papers dealing with polio, rabies, foot-and-mouth disease, Epstein-Barr virus, equine influenza and HIV were presented. There was much detailed work on the products of genetically engineered animal cells as well as a variety of enzymes (antithrombin and tissue plasminogen activator) and factors from the immune system. Most of the areas in which work on animal cells is progressing were brought up in some form in one or other of the sections of the proceedings.

The remarkable achievement of the last three years has been the licensing of three products made from cell substrates which are either oncogenic in one or other system or which have been derived from an oncogenic cell. That such a change could have occurred was due to the persistence of N. Finter at Wellcome and

colleagues in the USA, who have put together such convincing dossiers affirming the safety, efficacy and consistency of the products that the regulatory authorities were convinced that the balance between cost and benefit was well onto the side of benefit before they issued the licence.

There remain issues to be resolved. How much DNA should remain in a product, and how can we test for pathogenic agents whose effects and natures are completely unknown? How pure is pure and what does it mean to impute that a product is better than 98% or 99% pure? If impurities cannot be detected is the material pure? Probably not, but is that impurity of significant importance? Again, we have to consider the cost-benefit account and make decisions based on the probability that although there is a chance of cost, the benefit will be considerably in excess of that cost. These cold reasons do not help when there is the possibility of a death resulting from the administration of a biological. Were that to happen then some moralists would argue that all the benefit imaginable is not sufficient; however other minds may prevail and allow society to make progress even though the cost could be significant. In any event, the papers and discussions related in this volume take us to the forefront of the practicalities involved in this complex area, wherein progress is to be made by the judicious combination of experimental data and convincing guesses at the nature of what we are doing, linked with a philosophical approach which seeks to progress the well-being of our societies.

R. E. Spie  
Chairman, ESAC

# Contents

## Van Wezel Lecture 1

1. Contribution of animal cell technologies to healthcare 3

*B. J. Montagnon*

## Section 1 Animal cell lines 19

2. All cells are mortal 21

*L. Hayflick*

3. The ideal animal cell 32

*R. E. Spier*

4. Screening for and fermentation of high producer cell clones from recombinant BHK cells 44

*M. Wirth, S.-Y. Li, L. Schumacher, J. Lehmann, G. Zettlmeißl and H. Hauser*

5. The use of a statistical approach of the optimization of culture conditions of genetically engineered cell lines 52

*G. Mignot, V. Ganne, T. Faure, A. Pavirani and H. van de Pol*

## Section 2 Regulatory issues in animal cell culture 59

6. Significance of raw material screening for custom-designed cell culture media 61

*D. E. Wyatt and R. R. Dilling*

7. Contamination of foetal bovine serum by bovine diarrhoea virus (BVD or MDV) and other related pestiviruses 65

*C. Nguyen, J. Rouchouse and X. Pouradier-Duteil*

8. A multifaceted approach to assure that recombinant tPA is free of adventitious virus 68

*M. E. Wiebe, F. Becker, R. Lazer, L. May, B. Casto, M. Semense, C. Fautz, R. Garnick, C. Miller, G. Masover, D. Bergmann and A. S. Lubiniecki*

9. Retroviruses: new problems and new solutions in the safety testing of biologicals for regulatory approval 72  
*D. E. Onions, G. M. Lees and C. H. J. Sear*
10. Presence and transcription of endogenous retrovirus-like DNA sequences in CHO cells 76  
*F. M. Wurm, K. Anderson, S. R. Williams, J. Obijeski and W. R. Arathoon*
11. Chromosome damage in SV40 immortalized cell lines 82  
*P. Watts, U. Kreuzburg, D. Scott and C. MacDonald*
12. Endogenous retroviruses of continuous cell substrates 85  
*A. S. Lubiniecki*
13. Recombinant DNA containment considerations for large scale mammalian cell culture expression systems 93  
*C. Abreo, C. Hoerner, A. Lubiniecki, W. Wales and W. Wiebe*
14. Critical discussion of current good manufacturing practice with regard to the production of biologicals 99  
*V. G. Edy*
15. Concluding remarks on continuous cell lines, viruses and safety aspects 102  
*F. Horaud*

### **Section 3 New techniques 109**

16. Isolation of an unusual fastidious containment bacterium from an adherent cell line using a novel technique 111  
*J. M. Mowles, A. Doyle, M. J. Kearns and Y. Cerisier*
17. The use of acoustic densitometry for on-line monitoring of cell mass in mammalian cell reactors 114  
*D. G. Kilburn and J. B. Griffiths*
18. Methods to estimate number and quality of animal cells immobilized in carbohydrate gels 122  
*M. A. Al-Rubeai, N. H. Evans, C. A. Lambe, S. C. Musgrave and R. E. Spier*
19. Flow cytometric process monitoring of hybridoma cells in batch and perfusion culture 125  
*M. Klöppinger, G. Fertig, E. Fraune and H. G. Miltenburger*

20. The use of a fluorescent-activated cell sorter to monitor changes in cell specific productivity and its application to large scale culture 129  
*R. G. Rupp, E. Tahe and L. Peterson*
21. On line cell density estimation by spectrophotometry 134  
*I. Geahel, Y. Dordet, D. Duval, A. F. Dufan and J. Hache*
22. The 2-5A synthetase in bovine kidney cells; relation to cell growth and preliminary characterization 136  
*J. E. Severin, V. Chotteau, S. Lowagie, B. R. G. Williams and J. Werenne*
23. Use of the MTT assay for the study of hybridoma cells in homogeneous and heterogeneous cultures 143  
*M. Al-Rubeai and R. E. Spier*
24. Monoclonal-based ELISA and RIA methods for anabolic steroid monitoring 156  
*P. J. Williamson, M. Cody, K. W. Freebairn, N. T. Crosby and N. Jenkins*

## **Section 4 Differentiation of animal cells in culture 159**

25. Control of differentiation and growth of animal cells in culture 161  
*M. Raes*
26. Shear stress effects on anchorage-dependent and suspended mammalian cells 172  
*G. Kretzmer, U. Jämmrich and K. Schügerl*
27. Increased NADPH cytochrome C reductase activity – a marker for the action of chemical inducers of differentiation on melanoma cells 175  
*A. Fux, J. Nordenberg, L. Wasserman, Z. Malik, A. Peled and A. Novogrodsky*
28. Potentiation of the anti-proliferative effect of S-phase specific chemotherapeutics by guanosine 181  
*J. Nordenberg, C. Panet, A. Cyjon, E. Fenig, L. Wassermann, A. Novogrodsky and Y. Sidi*
29. The tissue inhibitor of metalloproteinases (TIMP): gene expression in mammalian cells 187  
*B. Coulombe, J-E. Severin, T. Marique, A. Ponton, J. Werenne and D. Skup*

30. Stability of antibody secretion by hybridomas 192  
*C. Harbour, C. P. Marquis, J. P. Barford and K. Z. Walker*
31. Glutamine synthetase amplification of TIMP expression in CHO cells 195  
*R. Field, M. Cockett and S. J. Froud*
32. Transfection of differentiated primary kidney cell cultures by early region SV40 virus DNA 198  
*D. M. Scott, H. Brezski, R. Kinne and C. MacDonald*

## **Section 5 Animal cell physiology 201**

33. Hydrodynamic effects on cultured hybridoma cells CRL 8018 in an agitated bioreactor 203  
*E. T. Papoutsakis and K. T. Kunas*
34. Hybridoma growth and antibody production under conditions of hyperosmotic stress 212  
*K. Øyaas, T. M. Berg, O. Bakke and D. W. Levine*
35. The effect of agitation on growth and antibody production of hybridoma cells – preliminary results 221  
*S. K. W. Oh, M. Al-Rubeai, A. N. Emery and A. W. Nienow*
36. Physiological studies of high cell density culture of different cell lines 224  
*B. Schumpp and E.-J. Schlaeger*
37. Hybridoma cell physiology 230  
*C. J. Morrison and P. G. Sanders*
38. Different oxygen sensitivities of vascular endothelial cells from porcine aorta and from human umbilical cord veins during fermentation in a stirred bioreactor 233  
*P. Friedl, J. J. Chang, R. Czapla and D. Tatje*
39. Kinetics and regulation of prourokinase production by human tumour kidney cells in perfused reactors 238  
*A. Wagner, S. Villermaux, A. Marc, J. M. Engasser and A. Einsele*
40. Flow cytometric studies during synchronous and asynchronous suspension cultures of hybridoma cells 241  
*M. Al-Rubeai, S. Rookes, A. N. Emery*

41. Growth characteristics and FMD virus susceptibilities of BHK21 cells proliferated on PHEMA microcarriers 246  
*M. Kiremikçi, I. Gürhan and E. Piskin*
42. Amino acid utilization by hamster cells during continuous perfusion 252  
*F. Buzsaky, K. Lie, E. Linder-Olsson*
43. Effect of amino acids on the growth and productivity of hybridoma cell cultures 257  
*D. Duval, I. Geahel, A. F. Dufau and J. Hache*

## **Section 6 Developments in serum-free media 261**

44. Development of a serum-free medium for hybridoma fermenter cultures 263  
*O.-W. Merten, H. Keller, L. Cabarie, J. Litwin and B. Flamand*
45. A low protein culture medium for antibody production 270  
*D. Wyatt, K. L. Humphrey and C. O'Rourke*
46. The growth of hybridoma cells in a serum and protein-free medium 273  
*J. Litwin*
47. Hybridoma cultivation in serum supplemented and serum-free media 277  
*M. Al-Rubeai and R. E. Spier*
48. Recombinant gamma interferon production by CHO cells in serum free medium 280  
*P. M. Hayter, D. Furlotte, M. Wilcox, E. M. A. Curling and N. Jenkins*
49. Insulin-like growth factor I (IGF1) stimulates the production of monoclonal antibodies in serum free medium 283  
*N. Chatzisavido, K. Lie and E. Linder-Olsson*
50. Growth promoting ability of human and egg transferrins in a serum free culture system 287  
*E. Bey, D. Botes, S. Marrs, R. L. Crookes and M. Shapiro*
51. The adaptation of hybridoma cell lines to grow and secrete monoclonal antibody in serum free/defined medium 291  
*S. A. Clark, D. Looby and J. B. Griffiths*

52. Enhancement of monoclonal antibody production by human-human hybridomas in serum-free media with immunoglobulin production stimulating factors 298

*H. Murakami, K. Toyoda, T. Sugahara and K. Yamada*

## **Section 7 Animal cell production systems 303**

53. Fully integrated, compact membrane reactor system for the large scale production of monoclonal antibodies 305

*F. Hofmann, W. Wrasidlo, D. DeWinter and S. Gallagher*

54. Techniques and equipment for animal cell cultivation 314

*A. Mizrahi*

55. Production of human PDGF-A in a stirred tank perfusion reactor and in a hollow fibre reactor 323

*V. Jäger, W. Eichner and J. Lehmann*

56. Production of anti-leukaemic factor from stroma cells in a stationary bed reactor on a new cell support 327

*A. Kadouri and D. Zipori*

57. Production of recombinant protein and monoclonal antibodies in continuous immobilized cell culture 333

*J. N. Vournakis, E. G. Hayman, N. G. Ray and A. S. Tung*

58. Immobilisation of animal cells in fixed and fluidised porous glass sphere reactors 336

*D. Looby and J. B. Griffiths*

59. Scale up with a new type of microcarrier: MICA® 345

*B. H. Wittek and P. Friedl*

60. Comparison of different cell culture systems for the production of monoclonal antibodies 350

*C. Mazars, S. Provenchere, L. Pouget, B. Pingeon and P. Henno*

61. High density culture of hybridomas recycling high molecular weight components 355

*M. Tokashiki, K. Hamamoto, Y. Takazawa and T. Arai*

62. High density microcarrier cell culture for viral vaccine production 361

*L. Fabry, B. Baijot, E. D'Hondt and M. Duchene*



63. Oxygen transfer and carrier mixing in large scale membrane stirrer cell culture reactors 366  
*J. Vorlop and J. Lehmann*
64. Cultivation of recombinant mammalian cells in a membrane stirrer reactor for production of human PDGF-A 370  
*D. Herbst, W. Eichner, R. Wagner and J. Lehmann*
65. The production of human interleukin 2 by recombinant mammalian cells 374  
*R. Wagner, H. Krafft and J. Lehmann*
66. Large scale production of monoclonal antibodies – a reality in any laboratory 378  
*A. Handa-Corrigan, S. Nikolay and R. E. Spier*
67. Process intensification for hybridoma cells by immersion of a hollow fibre bundle in a bioreactor 382  
*S. M. Rookes, D. Casson, A. N. Emery and M. Lavery*
68. Studies on mammalian cell growth in suspension culture 386  
*E. J. Schlaeger and B. Schumpp*
69. Optimizing the conditions for the fermentation of human umbilical cord vein endothelial cells 398  
*P. Friedl and D. Tatje*
70. Cultivation of rabies virus in Vero cells in two microcarrier culture systems 404  
*C. A. M. van der Velden-de Groot, R. X. van der Meer, G. van Steenis, W. Widjoatmodjo and E. C. Beuvery*
71. The CF 1000: second generation instrumentation for monitoring and control of bioreactors 408  
*G. Wiefen, G. Grumptmann, A. Lange, P. van Soest, M. E. F. Willems, N. van den Heuve, M. C. Philippi, C. A. M. van der Velden-de Groot and E. C. Beuvery*
72. Scale up of mammalian cell culture 412  
*D. F. Broad, M. E. Brown, A. P. Grant and L. A. Wood*

## **Section 8 Downstream processing 419**

73. Purification of mouse monoclonal antibodies from *in vitro* culture supernatants by immunoaffinity chromatography 421  
*H. Bazin, J. M. Malache, F. Nisol and F. Cormont*